ATXI (Avenue Therapeutics) Dividends Paid

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATXI Avenue Therapeutics Inc ATXI
29 GF Score
Price $0.50
! 2 Warning Signs
View Full Analysis

What is Avenue Therapeutics Dividends Paid?

Dividends Paid only applicable to companies reporting Cash Flow from Operations in direct method.

ATXI
29GF Score
Avenue Therapeutics Inc ATXI
Dividends Paid is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avenue Therapeutics Business Description

Address 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154
Avenue Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurologic and rare diseases. Its pipeline has shifted over time; the company previously advanced intravenous tramadol (IV tramadol) for post-operative acute pain but discontinued that program after regulatory setbacks. It has since pursued other candidates, including AJ201 for spinal and bulbar muscular atrophy (Kennedy's disease), licensed from AnnJi Pharmaceutical, and BAER-101 for epilepsy and panic disorders, licensed from Baergic Bio. Avenue Therapeutics operates as a single reportable segment and has no approved products or product revenue, relying on equity financings and licensing arrangements to fund research and development. The company is headquartered in the United States and its activities are conducted primarily domestically, with clinical development efforts aimed at the U.S. market.
29GF Score

Get the complete analysis for ATXI

Dividends Paid is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.50
Price